Patent application number | Description | Published |
20080279765 | Novel Imaging Agents for Fibrosis - The present invention provides a novel imaging agent targeting the mannose-6-phosphate (M6P) receptor suitable for the non-invasive visualization of fibrosis. A method for the preparation of the imaging agent is also provided by the invention, as well as a precursor for use in said method. The invention also provides a pharmaceutical composition comprising the imaging agent and a kit for the preparation of the pharmaceutical composition. In a further aspect, use of the imaging agent for in vivo imaging and in the preparation of a medicament for the diagnosis of a condition in which the mannose-6-phosphate receptor is upregulated is provided. | 11-13-2008 |
20080279771 | Novel Imaging Agents for Cancer - A novel imaging agent is described which comprises a semaphorin moiety and an imaging moiety. The novel imaging agent of the invention may be used in the diagnostic imaging of cancer and in particular, for targeting angiogenesis or metaplasia. Further aspects of the present invention presented herein include a method for the preparation of the imaging agent, a pharmaceutical composition comprising the imaging agent of the invention and a kit for the preparation of said pharmaceutical. | 11-13-2008 |
20080292547 | Novel Imaging Agents for Fibrosis - The present invention provides a novel imaging agent suitable for the non-invasive visualization of fibrosis. A method for the preparation of the imaging agent is also provided by the invention, as well as a precursor for use in said method. Also provided is a pharmaceutical composition comprising the imaging agent and a kit for the preparation of the pharmaceutical. In a further aspect, use of the imaging agent for in vivo imaging and in the preparation of a medicament for the diagnosis of a condition in which LOX is upregulated is provided. | 11-27-2008 |
20090238765 | Fluorescent Contrast Agent - The invention relates to contrast agents for imaging of diseases associated with inflammations. More specifically the invention provides optical imaging contrast agents for imaging of activated leukocytes and methods for imaging of such. The contrast agent changes its fluorescent properties upon reaction with oxidants produced by the activated leukocytes. | 09-24-2009 |
20100111865 | CONTRAST AGENTS - The present invention provides novel compounds and pharmaceutical compositions containing such compounds, wherein the compounds have affinity for proteoglycans. The compounds comprise an amino acid based core unit linked to positively charged moieties. The compounds further comprise at least one imaging moiety detectable in in vivo imaging making the compounds useful as diagnostic contrast agents for imaging of proteoglycans, such as heparan sulphate proteoglycans. | 05-06-2010 |
20110263975 | FLUORESCENT PROBES HAVING A POLYMERIC BACKBONE - The present invention relates to quenched fluorescent probes which arc activated by biochemical processes. The probes are designed such that intramolecular quenching occurs in the unactivated probe, but that the quencher moieties are cleaved from the probe under defined conditions rendering the probe fluorescent. Also disclosed are optical imaging agents suitable for in vivo imaging comprising the probes, as well as pharmaceutical compositions and kits, as well as in vivo imaging methods. | 10-27-2011 |
20110318273 | FLUORESCENT CONTRAST AGENTS - The invention relates to contrast agents for imaging of diseases associated with inflammations. More specifically the invention provides optical imaging contrast agents for imaging of activated leukocytes and methods for imaging of such. The contrast agent changes its fluorescent properties upon reaction with oxidants produced by the activated leukocytes. | 12-29-2011 |